Mohamed Bouattour

Clichy-sous-bois, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 119 publications

Implementation and evaluation of an ambulatory care pathway for intra-arterial treatment of primary liver cancer: study protocol for a multicentre randomised controlled hybrid type 1 trial (CHOC).

Implementation and evaluation of an ambulatory care pathway for intra-arterial treatment of primary liver cancer: study protocol for a multicentre randomised controlled hybrid type 1 trial (CHOC).

Journal: BMJ open

Published: August 06, 2026

Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer).

Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer).

Journal: Future oncology (London, England)

Published: May 11, 2026

Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.

Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.

Journal: The Lancet. Oncology

Published: May 08, 2026

Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.

Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.

Journal: Journal of hepatology

Published: April 09, 2026

Vessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab-bevacizumab.

Vessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab-bevacizumab.

Journal: JHEP reports : innovation in hepatology

Published: February 28, 2026

Atezolizumab-bevacizumab in very elderly with hepatocellular carcinoma: Age alone is not a limiting factor except in ALBI grade 3.

Atezolizumab-bevacizumab in very elderly with hepatocellular carcinoma: Age alone is not a limiting factor except in ALBI grade 3.

Journal: JHEP reports : innovation in hepatology

Published: February 16, 2026

Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.

Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.

Journal: The lancet. Gastroenterology & hepatology

Published: February 15, 2026

Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.

Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 14, 2026

Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma.

Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma.

Journal: JHEP reports : innovation in hepatology

Published: December 29, 2025

Clinical predictors of response to atezolizumab/bevacizumab in Child-Pugh B patients with hepatocellular carcinoma.

Clinical predictors of response to atezolizumab/bevacizumab in Child-Pugh B patients with hepatocellular carcinoma.

Journal: JHEP reports : innovation in hepatology

Published: December 29, 2025

Long-term Survival and Cure Fraction in Patients with Advanced Hepatocellular Carcinoma under Immunotherapy in Randomized Controlled Trials and Real-world Data.

Long-term Survival and Cure Fraction in Patients with Advanced Hepatocellular Carcinoma under Immunotherapy in Randomized Controlled Trials and Real-world Data.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 27, 2025

Second-line TKI after first-line immunotherapy-based treatment in advanced HCC: Reconstructed IPD meta-analysis.

Second-line TKI after first-line immunotherapy-based treatment in advanced HCC: Reconstructed IPD meta-analysis.

Journal: JHEP reports : innovation in hepatology

Published: December 16, 2025

Showing 1-12 of 119

Last Updated: 09/26/2026